ArticleBMC surgery2026
Bitter-sweet? The role of glycemic control in breast reduction surgery.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe American Society of Plastic Surgeons guidelines emphasize the need for additional evidence regarding perioperative glycemic control in patients with diabetes undergoing breast reduction surgery. This study evaluates the association between preoperative hemoglobin A1c (HbA1c) levels and postoperative complications in patients with diabetes undergoing reduction mammaplasty.
methodsA retrospective cohort study of the National Surgical Quality Improvement Program (NSQIP) database was performed, identifying patients diagnosed with diabetes who underwent breast reduction surgery from 2021 to 2023. Patients were stratified by preoperative HbA1c levels: well-controlled (HbA1c < 6.5%) versus poorly controlled (HbA1c ≥ 6.5%). Demographics, surgical characteristics, and 30-day postoperative outcomes were compared between groups. Multivariable logistic regression analysis was performed to identify independent risk factors for complications.
resultsA total of 364 female patients with diabetes met the inclusion criteria, of whom 293 (80%) had non–insulin-dependent and 71 (20%) had insulin-dependent diabetes. Based on HbA1c levels, 206 patients (57%) had well-controlled diabetes, and 158 (43%) had poorly controlled diabetes. The groups were comparable in age, BMI, and surgical characteristics. The overall complication rate was 10.7% (n = 39), with superficial surgical site infections being the most common (n = 22, 6.0%). Patients with poorly controlled diabetes had higher rates complications overall (13.0% vs. 9.2%, p = 0.29) and readmission (4.4% vs. 1.0%, p = 0.044). In multivariable analysis, HbA1c ≥ 6.5% was independently associated with an increased risk of complications (OR 2.2, 95% CI 1.0–4.7, p = 0.047).
conclusionPatients with diabetes and poorly controlled glycemic status demonstrate a higher likelihood of postoperative complications following breast reduction surgery, although the association reached only borderline statistical significance. These findings support the clinical plausibility that suboptimal glycemic control may contribute to increased perioperative risk and may help inform patient counseling and surgical decision-making in this population. Further research is needed to clarify the extent to which preoperative glycemic optimization influences outcomes in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.